First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.

Sudhoff H

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery28 Jul 2025Cited by 2 (Europe PMC)

PMID40721956DOI10.1007/s00405-025-09604-5PepBankPUB-40721956

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In 7 adults on GLP-1 receptor agonists (semaglutide or tirzepatide), patulous Eustachian tube developed after 4-10 months of therapy.
In plain wordsSeven adults on GLP-1 drugs (semaglutide or tirzepatide) developed an open Eustachian tube in the ear after 4-10 months.
Peptide
Semaglutide
Outcome
Not applicablePatulous Eustachian tube after 4-10 months of therapy
Study
n = 7
Outcome group
Adverse events · Whole body
Source sentences
Summary
Seven patients (5 female, 2 male; age 28-56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4-10 months of GLP-1 therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4072195601
02HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome
In 7 adults on GLP-1 receptor agonists (semaglutide or tirzepatide), patulous Eustachian tube developed after 4-10 months of therapy.
In plain wordsSeven adults on GLP-1 drugs (semaglutide or tirzepatide) developed an open Eustachian tube in the ear after 4-10 months.
Peptide
Tirzepatide
Outcome
Not applicablePatulous Eustachian tube after 4-10 months of therapy
Study
n = 7
Outcome group
Adverse events · Whole body
Source sentences
Summary
Seven patients (5 female, 2 male; age 28-56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4-10 months of GLP-1 therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4072195602
03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome
In 7 adults on GLP-1 receptor agonists (semaglutide or tirzepatide) who developed patulous Eustachian tube, weight loss ranged from 8.2 to 18.7% of baseline.
In plain wordsIn seven adults on GLP-1 drugs, weight loss ranged from 8.2 to 18.7% of starting weight.
Peptide
Semaglutide
Outcome
DecreaseWeight loss range
Study
n = 7
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight loss ranged from 8.2 to 18.7% of baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4072195603
04HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome
In 7 adults on GLP-1 receptor agonists (semaglutide or tirzepatide) who developed patulous Eustachian tube, weight loss ranged from 8.2 to 18.7% of baseline.
In plain wordsIn seven adults on GLP-1 drugs, weight loss ranged from 8.2 to 18.7% of starting weight.
Peptide
Tirzepatide
Outcome
DecreaseWeight loss range
Study
n = 7
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight loss ranged from 8.2 to 18.7% of baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4072195604
05HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In 7 adults with patulous Eustachian tube on GLP-1 receptor agonists (semaglutide or tirzepatide), autophony occurred in 7 of 7, aural fullness in 6 of 7 and audible breathing in 5 of 7.
In plain wordsAmong seven adults on GLP-1 drugs with an open Eustachian tube, all heard their own voice loudly and most felt ear fullness.
Peptide
Semaglutide
Outcome
Not applicableSymptoms of patulous Eustachian tube
Study
n = 7
Outcome group
Adverse events · Whole body
Source sentences
Summary
Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one's own breathing (5/7).
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4072195605
06HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome
In 7 adults with patulous Eustachian tube on GLP-1 receptor agonists (semaglutide or tirzepatide), autophony occurred in 7 of 7, aural fullness in 6 of 7 and audible breathing in 5 of 7.
In plain wordsAmong seven adults on GLP-1 drugs with an open Eustachian tube, all heard their own voice loudly and most felt ear fullness.
Peptide
Tirzepatide
Outcome
Not applicableSymptoms of patulous Eustachian tube
Study
n = 7
Outcome group
Adverse events · Whole body
Source sentences
Summary
Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one's own breathing (5/7).
2 context sentences(design, population, supporting numbers)
Summary · context
To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic^®] or tirzepatide [Mounjaro^®]).
Summary · context
All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4072195606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.